Loading...

TNGX TANGO THERAPEUTICS INC Management Changes 8-K Filing

TNG

TNGX

TANGO THERAPEUTICS INC

(TNGX)

2026 8-K

Board Resignations

Management Change

Leadership Changes

Earnings Report

Leadership Changes

Director Appointment

Stock Sales Update

Financial Results Update

Stock Offering Announcement

Financial Update

Management Change

Financial Statements

Increase in authorized shares

Financial Statements

New Partnership

Funding Increase

Clinical Trial Update

Filing with Quantitative Data

Financial Update

Filing with Quantitative Data

Private Placement

Quantitative Data

Filing with Quantitative Data

External Links:

On January 2, 2026, Tango Therapeutics, Inc. appointed Sung H. Lee as a new director, granting him stock options for 60,000 shares at $8.93 and a restricted stock unit for 10,000 shares, alongside a $40,000 annual retainer. This filing is significant as it reflects changes in management and governance structure.

AI Assistant

TANGO THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.